Nasdaq

Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer

MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...
Star Tribune

Prostate cancer test leads Bio-Techne's expansion into diagnostics

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Business Wire

Massive Bio, Inc. to Partner With Veterans Prostate Cancer Awareness and Self-Care Catalysts to Accelerate Clinical Trial Enrollment and Digital Health Solutions

NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...
Nasdaq

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...
FierceBiotech

Massive Bio teams up with veterans nonprofit to increase prostate cancer research, trial enrollment

Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer. Massive Bio, Veterans Prostate Cancer Awareness and ...
MedCity News

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
manilatimes

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
BioTechniques

Targeting prostate cancer’s Achilles’ heel

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for new and more effective treatments. An international team has uncovered two ...
Business Wire

Nanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United States

CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...
CBS News

Biotechs aim for noninvasive prostate cancer biopsies

What if doctors could screen men for prostate cancer without a painful, and often unneeded, biopsy? A handful of biotech firms are working on techniques that would instead use simple blood or urine ...
BioWorld

Advanced prostate cancer antibody successful in dogs

A Japanese study has shown that targeting the chemokine receptor CCR4 using treatment with the monoclonal antibody (MAb) mogamulizumab (Poteligeo, Kyowa, Amgen) depleted immune regulatory T cells ...